

Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Signs Distribution Agreement and Secures First Order from China

Feb 19 2019, 6:50 AM EST

Eastern Missouri Court Rules in Favor of Kane Biotech in Lawsuit Against Nestle Purina

Feb 4 2019, 8:30 AM EST

Kane Biotech Expands Previously-Announced Single Largest Order of bluestem™ Products

Jan 30 2019, 8:30 AM EST

Stock Overview

Symbol	KNBIF
Exchange	OTCQB
Market Cap	5.54m
Last Price	\$0.0691
52-Week	\$0.04398 - \$0.08394

02/15/2019 03:36 PM EST

Investor Relations

Edison Advisors
Tirth Patel
Vice President, Investor Relations
295 Madison Avenue, 18th Floor
New York, NY 10017
T: 646-653-7035
M: 386-295-2215
tpatel@edisongroup.com

Management Team

Marc Edwards

Director, Interim Chief Executive Officer

Ray Dupuis

Chief Financial Officer

Gordon Guay, Ph.D.

Chief Scientific Officer

Grant Humphrey

Vice President, Sales

Nanda Yakandawala

Senior Research Scientist

Wendy Nachtigall

Director, Marketing

Andrea Gordon

Director, Regulatory and Quality Control

Kane Biotech Inc.

162-196 Innovation Drive
Winnipeg, Manitoba R3T 2N2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.